120 related articles for article (PubMed ID: 32997181)
1. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma.
Fu F; Sun X; Li Y; Liu Y; Shan Y; Ji N; Wang X; Lu J; Sun S
Eur Radiol; 2021 Apr; 31(4):1863-1871. PubMed ID: 32997181
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
Vivoda Tomšič M; Korošec P; Kovač V; Bisdas S; Šurlan Popovič K
BMC Cancer; 2022 Feb; 22(1):191. PubMed ID: 35184730
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy.
Xu L; Ge X; Sun N; Liu X
Acta Radiol; 2020 Oct; 61(10):1316-1325. PubMed ID: 32053003
[TBL] [Abstract][Full Text] [Related]
6. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses.
Lund KV; Simonsen TG; Kristensen GB; Rofstad EK
Radiat Oncol; 2020 Apr; 15(1):79. PubMed ID: 32293487
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
8. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of quantitative dynamic contrast-enhanced magnetic resonance imaging for the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer].
Zhu YJ; Li Y; Jiang J; Zhang W; Xue LY; Zhou AP; Jiang LM
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):765-770. PubMed ID: 31648499
[No Abstract] [Full Text] [Related]
10. Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.
Chen BB; Lu YS; Yu CW; Lin CH; Chen TW; Wei SY; Cheng AL; Shih TT
Eur Radiol; 2018 Nov; 28(11):4860-4870. PubMed ID: 29770848
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced magnetic resonance imaging-based radiomics for the prediction of progression-free survival in advanced nasopharyngeal carcinoma.
Li WZ; Wu G; Li TS; Dai GM; Liao YT; Yang QY; Chen F; Huang WY
Front Oncol; 2022; 12():955866. PubMed ID: 36338711
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
13. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of preoperative dynamic contrast-enhanced magnetic resonance imaging in epithelial ovarian cancer.
Lindgren A; Anttila M; Arponen O; Rautiainen S; Könönen M; Vanninen R; Sallinen H
Eur J Radiol; 2019 Jun; 115():66-73. PubMed ID: 31084761
[TBL] [Abstract][Full Text] [Related]
15. [The value of DCE-MRI in predicting IDH gene mutation of high-grade gliomas].
Lu HT; Xing W; Zhang YW; Qin HP; Wu RH; Ding JL
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3105-3109. PubMed ID: 31648456
[No Abstract] [Full Text] [Related]
16. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
17. Prediction of radiosensitivity in primary central nervous system germ cell tumors using dynamic contrast-enhanced magnetic resonance imaging.
Feng C; Gao P; Qiu X; Qian T; Lin Y; Zhou J; Sui B
Chin J Cancer Res; 2015 Jun; 27(3):231-8. PubMed ID: 26157319
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients.
Wu G; Huang W; Xu J; Li W; Wu Y; Yang Q; Liu K; Zhu M; Balasubramanian PS; Li M
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1771-1780. PubMed ID: 34398299
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI.
Guo P; Liu Z; Yan F; Wang J; Wei L; Lv H; Wang Z; Xian J
Acta Radiol; 2016 Dec; 57(12):1490-1496. PubMed ID: 27012277
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.
Kuchcinski G; Le Rhun E; Cortot AB; Drumez E; Duhal R; Lalisse M; Dumont J; Lopes R; Pruvo JP; Leclerc X; Delmaire C
Eur Radiol; 2017 Sep; 27(9):3733-3743. PubMed ID: 28210799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
